GI-MAP

← Back to Lab Reference Library

Category: Gut Health  |  Also known as: GI Microbial Assay Plus, qPCR Stool Analysis, Comprehensive Stool Test  |  Sample: Single stool collection (preservative tube provided; no refrigeration needed once in tube)

1. What This Test Measures

The GI-MAP (GI Microbial Assay Plus) is a comprehensive stool analysis that uses quantitative polymerase chain reaction (qPCR) technology to detect and quantify the DNA of organisms and biomarkers from a single stool sample. Unlike traditional stool cultures that require organisms to grow on artificial media (missing anaerobes, fastidious organisms, and intracellular parasites), qPCR detects organism DNA directly, providing superior sensitivity and the ability to quantify exactly how much of each organism is present.

The GI-MAP report is organized into several sections. The pathogen section identifies organisms that cause disease in any quantity: H. pylori (with virulence factors cagA and vacA), C. difficile (with toxin genes), Salmonella, Shigella, Campylobacter, pathogenic E. coli strains, and parasites including Giardia, Cryptosporidium, Entamoeba histolytica, and others. The opportunistic organisms section identifies bacteria and yeast that are normal residents of the gut at low levels but become pathogenic when overgrown: Candida species, Pseudomonas, Klebsiella, Citrobacter, Staphylococcus, and Enterococcus. The commensal bacteria section quantifies beneficial organisms: Lactobacillus, Bifidobacterium, Akkermansia muciniphila, Faecalibacterium prausnitzii, and Bacteroidetes/Firmicutes ratios.

The intestinal health markers section provides biomarkers that assess mucosal immune function (secretory IgA), intestinal inflammation (calprotectin), pancreatic digestive function (elastase-1), intestinal permeability (zonulin), estrogen metabolism (beta-glucuronidase), gluten immune reactivity (anti-gliadin antibody), and occult blood. These markers transform the GI-MAP from a simple "bug hunt" into a comprehensive assessment of gut ecosystem health, immune function, and digestive capacity.

2. Why This Test Matters

• Identifies infections missed by standard testing: qPCR detects organisms that standard stool cultures miss in 30 to 50% of cases. Parasites, anaerobes, and intracellular organisms are particularly underdetected by culture-based methods. Many patients with chronic GI symptoms and "negative" conventional stool tests have identifiable pathogens on GI-MAP
• Quantifies dysbiosis: the GI-MAP does not just identify what is present; it quantifies how much. Opportunistic organisms like Candida or Klebsiella may be present at normal levels or overgrown. The quantification determines whether treatment is needed and guides treatment intensity
• H. pylori with virulence factors: the GI-MAP detects H. pylori DNA and its virulence factors (cagA and vacA) that determine clinical significance. H. pylori cagA-positive strains carry significantly higher gastric cancer and peptic ulcer risk than cagA-negative strains
• Intestinal permeability assessment: zonulin on the GI-MAP provides a functional marker of intestinal barrier integrity. Elevated zonulin indicates increased paracellular permeability, the mechanism linking gut dysfunction to systemic inflammation, autoimmune activation, and food sensitivities
• Digestive function: pancreatic elastase-1 below 200 mcg/g indicates exocrine pancreatic insufficiency, a common and underdiagnosed cause of maldigestion, bloating, and nutrient malabsorption. Many patients with chronic bloating have unrecognized pancreatic insufficiency identified only by stool elastase testing
• Mucosal immune status: secretory IgA (sIgA) is the frontline immune defense of the gut mucosa. Low sIgA indicates mucosal immune deficiency (increased susceptibility to gut infections and food reactivity). Elevated sIgA indicates active immune response to a current pathogen or antigen
• Estrogen metabolism: beta-glucuronidase is a bacterial enzyme that deconjugates estrogen metabolites in the gut, allowing them to be reabsorbed rather than excreted. Elevated beta-glucuronidase increases estrogen recirculation, contributing to estrogen dominance, hormonal imbalances, and estrogen-sensitive conditions

3. GI-MAP Report Sections

Section	What It Measures	Clinical Significance
Pathogens	H. pylori, C. difficile, Salmonella, parasites, viruses	Any detected level is clinically significant and requires treatment
Opportunistic Organisms	Candida, Pseudomonas, Klebsiella, Citrobacter, Staph	Normal at low levels; pathogenic when overgrown above reference
Beneficial Commensals	Lactobacillus, Bifidobacterium, Akkermansia, F. prausnitzii	Low levels indicate depleted protective flora; target restoration
Intestinal Health	Calprotectin, sIgA, elastase, zonulin, beta-glucuronidase	Functional markers of inflammation, immunity, digestion, permeability
Antibiotic Resistance	Resistance genes detected in identified organisms	Guides antibiotic selection if pharmaceutical treatment needed

4. Key Intestinal Health Markers Interpreted

Marker	Normal Range	Clinical Interpretation
Calprotectin	Below 120 mcg/g	Above 120: intestinal inflammation (IBD, infection, significant mucosal damage). Above 250: strongly suggestive of inflammatory bowel disease; GI referral indicated
Secretory IgA	510 to 2010 mcg/g	Low: mucosal immune deficiency; increased infection susceptibility. High: active immune response to current pathogen or antigen exposure
Elastase-1	Above 200 mcg/g	Below 200: exocrine pancreatic insufficiency; impaired fat and protein digestion; pancreatic enzyme replacement indicated
Zonulin	Below 107 ng/g	Elevated: increased intestinal permeability (leaky gut); tight junction dysfunction; drives systemic inflammation and food reactivity
Beta-glucuronidase	Below 2892 U/g	Elevated: increased estrogen recirculation; bacterial enzyme deconjugates estrogen for reabsorption; contributes to estrogen dominance
Anti-gliadin sIgA	Below 24 U/g	Elevated: mucosal immune reactivity to gluten; suggests gluten sensitivity even if serum celiac markers are negative

5. GI-MAP in the Complete Gut Health Assessment

Test	What It Adds	When to Use
GI-MAP (this page)	Organisms, commensals, pathogens, intestinal health markers	First-line comprehensive gut assessment
SIBO Breath Test	Small intestinal bacterial overgrowth (hydrogen/methane)	When bloating is the dominant symptom; SIBO suspected
Food Sensitivity Panel	IgG-mediated food reactivities	When food reactions persist after gut restoration
hs-CRP	Systemic inflammation reflecting gut-driven inflammation	Baseline and post-treatment to track systemic impact
Zonulin (serum)	Systemic marker of intestinal permeability	Complements stool zonulin for systemic permeability assessment
Fasting Insulin	Metabolic context; dysbiosis drives insulin resistance	When metabolic dysfunction coexists with gut symptoms

6. Symptoms That Indicate GI-MAP Testing

7. What Common GI-MAP Findings Mean

• H. pylori detected (especially cagA+): H. pylori infects approximately 50% of the global population. cagA-positive strains carry the highest risk for gastric ulcers, gastric cancer, and atrophic gastritis. Treatment is recommended for all symptomatic infections and for asymptomatic cagA-positive infections due to the cancer risk
• Candida overgrowth: Candida species are normal gut residents at low levels. Overgrowth (typically above 1e3 to 1e4 on qPCR) produces bloating, sugar cravings, brain fog, oral thrush, and vaginal yeast infections. Driven by antibiotic exposure, high-sugar diets, immune suppression, and depleted Lactobacillus populations that normally keep Candida in check
• Low Akkermansia muciniphila: Akkermansia is a keystone species that maintains the intestinal mucus layer. Low Akkermansia is associated with increased intestinal permeability, metabolic syndrome, insulin resistance, and inflammatory conditions. Polyphenol-rich foods (berries, green tea, pomegranate) and prebiotic fibers support Akkermansia growth
• Low Faecalibacterium prausnitzii: F. prausnitzii is the primary butyrate producer in the human gut. Butyrate is the preferred fuel for colonocytes and is essential for maintaining the intestinal barrier. Low F. prausnitzii is consistently associated with inflammatory bowel disease, IBS, and increased intestinal permeability
• Elevated zonulin: confirms increased intestinal permeability. Zonulin is the protein that reversibly opens tight junctions between intestinal epithelial cells. Chronic elevation allows food-derived and microbial antigens to enter the bloodstream, driving systemic inflammation, food sensitivities, and autoimmune activation
• Low secretory IgA: indicates mucosal immune deficiency. The gut mucosa cannot adequately defend against pathogens and food antigens. These patients are more susceptible to recurrent gut infections and food reactivity. sIgA support includes colostrum, saccharomyces boulardii, and addressing chronic stress (cortisol suppresses sIgA production)
• Elevated beta-glucuronidase: certain gut bacteria (particularly Firmicutes species) produce this enzyme, which deconjugates estrogen metabolites bound for fecal excretion, allowing estrogen reabsorption into the bloodstream. This increases circulating estrogen and contributes to estrogen dominance, PMS, heavy periods, fibroids, and estrogen-receptor-positive breast cancer risk. Calcium-d-glucarate supplementation (1500mg daily) inhibits beta-glucuronidase activity

8. How to Optimize Gut Ecosystem Health

9. Related Lab Tests

10. When Testing Is Recommended

• Chronic GI symptoms (bloating, diarrhea, constipation, abdominal pain, reflux) not resolved by standard evaluation or dietary changes
• Suspected intestinal dysbiosis or SIBO with persistent symptoms despite breath test-guided treatment
• Autoimmune disease evaluation: gut permeability and dysbiosis are primary drivers of autoimmune activation through molecular mimicry and immune dysregulation
• Skin conditions with suspected gut origin: acne, eczema, rosacea, psoriasis (gut-skin axis)
• New or worsening food intolerances suggesting compromised gut barrier or mucosal immune dysfunction
• Chronic fatigue or brain fog with GI component (gut-brain axis)
• Histamine intolerance: GI-MAP identifies histamine-producing bacterial species contributing to histamine burden
• Hormonal imbalances (estrogen dominance): beta-glucuronidase assessment on the GI-MAP identifies bacterial estrogen recirculation
• Post-antibiotic recovery: assess microbiome damage and guide targeted restoration
• Pre- and post-treatment assessment: baseline GI-MAP before antimicrobial protocol, repeat at 8 to 12 weeks to confirm eradication and restoration

11. Clinical Perspective

12. Frequently Asked Questions